Intech Investment Management LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Intech Investment Management LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 48,263 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. Russell Investments Group Ltd. raised its position in shares of TG Therapeutics by 133.5% in the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 29,923 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of TG Therapeutics during the 1st quarter worth $91,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of TG Therapeutics by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock worth $1,303,000 after purchasing an additional 5,015 shares during the last quarter. Cetera Advisors LLC purchased a new stake in shares of TG Therapeutics in the first quarter valued at $622,000. Finally, Opaleye Management Inc. increased its stake in TG Therapeutics by 2.9% in the first quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock valued at $34,679,000 after purchasing an additional 65,000 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

TGTX opened at $35.00 on Thursday. TG Therapeutics, Inc. has a twelve month low of $12.32 and a twelve month high of $36.84. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of -349.97 and a beta of 2.19. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a fifty day simple moving average of $26.00 and a 200 day simple moving average of $21.95.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s revenue was down 49.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 earnings per share. Equities research analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on TGTX. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday. HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.